Introduction
Human cytomegalovirus (HCMV), a ubiquitous human-specifi c DNA virus of the herpesviridae family, is the commonest agent causing congenital infection in humans throughout the globe. [1, 2] The seroprevalence of infection with HCMV varies in the developed and developing countries with racial, ethnic, cultural and socioeconomic factors all contributing to these differences. In the developed world, the seroprevalence of the virus blood as a sample, include demonstration of HCMV DNA by PCR and detection of HCMV pp65 antigen. Besides urine, saliva has been used as a sample for demonstration of HCMV DNA by PCR with results comparable to those obtained from urine. [6, 7] The aim of this study was to compare PCR from urine, saliva and blood, serology (anti-HCMV IgM) and antigen detection (HCMV pp65 antigenaemia) for the diagnosis of HCMV infection in symptomatic neonates and infants. Since saliva is a convenient sample to collect and process, and no reports are available from India regarding its utility for PCR, we wanted to evaluate it in comparison with other samples like urine and blood. As detection of anti-HCMV IgM is a commonly used test for the diagnosis of congenital HCMV infection, we also compared this modality with PCR. There are only a few reports for the use of pp65 antigenaemia in the diagnosis of congenital infections, [8] even though it is an established test for diagnosing active HCMV infection in adults, especially in transplant recipients.
Materials and Methods
The study was carried out in the virology laboratory of the department of Microbiology, All India Institute of Medical Sciences (AIIMS), New Delhi between July 2005 and July 2007. Neonates and infants with suspected HCMV infection, referred from the neonatology unit, the outpatients department or wards of the department of Paediatrics, were included in the study. The inclusion criteria were any one or more of the following: neonatal hepatitis, SGA (birth weight <10 th percentile for the period of gestation), microcephaly, hydrocephalus, hepatomegaly, splenomegaly, petechial/purpuric rash, cataract, chorioretinitis and corneal opacity. Exclusion criteria included sepsis, inherited primary microcephaly, hepatomegaly and/or splenomegaly due to inborn errors of metabolism, and SGA due to antenatal causes. The study was approved by the ethics committee of the institute. Informed written consent was obtained from the mothers of all infants included in the study. Table 1 enlists the assays performed in the study.
The steps involved in sample collection, transport and processing are described briefl y: For urine, about 5-10 ml of freshly voided, clean catch midstream urine was collected in a sterile 15 ml screw-capped tube and transported to the laboratory immediately. The sample was treated with antibiotics (Penicillin 100 IU/ml and Streptomycin 100 g/ml) and kept at 4°C overnight. The next day, it was clarifi ed by centrifugation and the supernatant was used for PCR. The remaining sample was stored at −80°C. Saliva was collected by rubbing a plain cotton-tipped sterile swab across the buccal mucosa over the molars in the proximity of the Stenson's duct and then over the fl oor of the mouth anterior to the tongue. The swab was subsequently immersed in 1.5 ml of 2-sucrose phosphate Viral Transport Media (VTM) and transported to the laboratory immediately. There, the tip of the swab was pressed thoroughly against the side of the tube in order to express out all the saliva into the medium and then discarded appropriately. The VTM containing the saliva was then centrifuged at 1,000 rpm for 10 min. at 4°C, and the supernatant used for PCR. The remaining sample was stored at −80°C. A total of about 3 ml blood was collected aseptically by peripheral venepuncture, 2 ml of which was collected in an ethylenediaminetetraacetic acid (EDTA) vaccutainer (Becton Dickinson, USA), and the remaining 1 ml in a plain sterile vial. The EDTA-treated blood was used for HCMV pp65 antigenaemia assay and for PCR. The blood collected in the plain vial was left undisturbed for an hour, allowing the blood to clot, following which the clot was carefully removed and the serum separated for the anti-HCMV IgM assay.
DNA was extracted from urine and saliva using a commercially available kit (QIAamp Viral RNA Minikit, Qiagen Inc, CA, USA). Amplifi cation of HCMV DNA was performed by an in-house standardised nested PCR for the gB gene, using published primers. [9] The external primers were gB1138 5′ CAAGARGTGAACATGTCCGA 3′ and gB1638 3′ GTCACGCAGCTGGCCAG 5′ which allowed the amplifi cation of a 501bp sequence; the inner primers were gB1276 5′GGTTTGGTGGTGTTCTGGCA3′ and gB1524 3′CACACACCAGGCTTCTGCGA5′ which allowed the amplifi cation of a 249 bp sequence from the gB gene, following a published protocol. [10] The amplifi ed products were run on agarose gel and visualised on a ultraviolet (UV) transilluminator after ethidium bromide staining [ Figure 1 ]. A standard strain of HCMV (AD 169) was used as the positive control.
The anti-HCMV IgM (-capture) enzyme-linked immunosorbent assay (ELISA) was performed using a commercial kit (CMV IgM Capture Smart Test Diagnostics, Orgenics Ltd, Israel) following manufacturer instructions. The HCMV pp65 antigenaemia assay [ Figure 2 ] was performed using a commercially available kit (CMV Brite Turbo, Biotest Diagnostic Corp. Denville, NJ, USA) following manufacturer instructions. 
Results
Thirty-one neonates and infants with suspected congenital infection, who fulfi lled the inclusion and exclusion criteria were included in the study. Twenty-two (71%) of these infants were male and the remaining 9 (29%) were female. The median age at presentation was 13 weeks (range: 1 day to 10 months). Initially, PCR for HCMV DNA from urine and detection of anti-HCMV IgM were performed, and the results of these two assays shown in Table 2 .
Twenty-two (70.9%) infants were positive by both tests, while 5 (16.1%) were negative by both tests, giving a concordance of 86.7% between the two tests. Three infants of the 31 (9.7%) were positive for anti-HCMV IgM but negative for HCMV DNA, whereas 1 infant (3.2%) was negative for anti-HCMV IgM but positive for HCMV DNA.
Of the 22 infants who were positive for both HCMV IgM and urine PCR, salivary swabs could be collected in 18. A detailed history with fi ndings of physical examination and other radiological investigations were recorded for the latter. HCMV DNA was detected in the saliva of all 18 (100%) infants. However, HCMV DNA was detectable in the whole blood of only 7 (38.8%) of these 18 infants, while the pp65 antigenaemia assay was positive in only 1 neonate (5.5%) who was born premature.
The clinical and laboratory data of the 18 infants positive for both HCMV DNA in urine by PCR and anti-HCMV IgM are given in Table 3 . Hepatosplenomegaly was the commonest clinical manifestation in 16 (88.9%), whereas direct (conjugated) hyperbilirubinaemia was observed in 11 (61.1%), with clinically apparent icterus in 9 (50%) infants.
Discussion
In this study, we intended to compare the various modalities utilised in the diagnosis of congenital HCMV infection in neonates and infants. The commonest samples received in the virology laboratory are serum (for anti-HCMV IgM) and urine (for HCMV DNA by PCR). Further, we evaluated the usefulness of saliva and blood for detection of HCMV DNA by PCR, and also of HCMV pp65 antigenaemia by immunofl uorescence as an antigen detection assay in this scenario. Table 2 has compared the results of IgM (-capture) ELISA with urine PCR for the 31 infants included in the study. Twenty-two infants (70.9%) had both the tests positive. Hence, in 25 (80.6%) infants with suspected congenital HCMV infection, the anti-HCMV IgM assay was able to pick up evidence of infection in them. On the other hand, PCR for HCMV DNA from urine was positive in 23 of 31 (74.2%) of these cases. The slight lower positivity of PCR can be explained by the intermittent excretion of the virus from the kidneys in congenital HCMV infection. Earlier studies [11, 12] have also demonstrated that although PCR is highly specifi c, anti-HCMV IgM is more convenient and has a higher or similar sensitivity to PCR, particularly in infants who present to the hospital late after birth. In our study, the median age of presentation was 13 weeks. One infant had a negative Anti-HCMV IgM but urine PCR was positive for HCMV DNA. The age at presentation for this baby was 10 months and his clinical profi le revealed hepatosplenomegaly since birth. The negative IgM ELISA can be explained by the disappearance of anti-HCMV IgM by this age. Anti-HCMV IgM is known to sharply drop in titre in 2-3 months after onset of infection and are virtually undetectable within 12 months. [13] The PCR was reconfi rmed by testing another target gene (gN) of HCMV, indicating that it was a true positive result.
The results of saliva PCR and urine PCR were totally concordant for the 18 neonates that these tests were performed on. Each of the 18 neonates/infants whose urine PCRs were positive for HCMV DNA also had their saliva PCR positive for the same. This supports the results of earlier studies and shows that saliva is as reliable as urine for detection of HCMV infection in neonates and infants. [6] Another study from Brazil also revealed a 99.7% agreement between the results of both the samples. Further, the authors recommended the use of saliva for detection of HCMV DNA via PCR as an acceptable technique for large-scale detection of congenital HCMV infection (e.g. neonatal screening programmes). [7, 14] In a previous study [15] that looked at various diagnostic modalities, the sensitivities of HCMV DNAemia (by PCR), antigenaemia and anti-HCMV IgM were 100%, 42.5% and 70.7% respectively, while specifi city was 100% for all assays. This study concluded that determination of viral DNA in blood by PCR at birth appears to be as sensitive and specifi c as virus recovery from urine. A previous study from Italy [16] detected HCMV pp65 antigen in 10 (29.4%) of 34 newborn infants. However, in our study, PCR for HCMV DNA from blood was positive in only 7 (38.3%), while the assay for HCMV pp65 antigenaemia was positive in only 1 (5.6%) of the 18 infants. It should be noted that the babies in both these studies [15, 16] were tested at a much earlier age compared to those in our study. Except for one premature neonate who could be tested on day 1 of life, we could not perform this assay in the initial few weeks of birth, since the median age of presentation of our cohort was 13 weeks. The sensitivity of HCMV pp65 antigenaemia assay has been reported to be low except in premature neonates, especially if tested within the few days of birth. [16] The lower positivity of whole blood PCR can be explained by the fact that viraemia does not persist beyond a few days of birth, after which the virus is localised in the epithelia of the kidney and salivary glands and is shed (and thence detected) mainly in the urine and saliva. [2] 
Conclusion
The study concludes that either urinary or salivary PCR combined with anti-HCMV IgM are the most appropriate assays to detect congenital HCMV infection in our setting. Saliva is a convenient, noninvasive sample and can substitute urine, especially in the outpatient and fi eld settings. Saliva as a sample combines convenience with high sensitivity in the diagnosis of congenital HCMV infection. To the best of our knowledge, this is the fi rst study evaluating salivary PCR for the diagnosis of congenital HCMV infection from the country.
